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Abstract 
Epidermal growth factor receptor- tyrosine kinase inhibitor (EGFR-TKI) is one of the 
genetic targeted medicines that is used to treat non-small-cell lung cancer. However, because 
EGFR-TKIs have a specific target, they are not believed to benefit all non-small-cell cancer 
patients.  
 We conducted a meta-analysis synthesizing 9 randomized controlled trials (RCTs) to 
systematically evaluate the effectiveness of EFGR-TKIs among two patient populations: 
unselected patients with unknown EGFR mutation status and selected patients harboring EGFR 
mutation 
 Among unselected patients, the efficacy of EGFR-TKIs is inferior to chemotherapy. The 
hazard of disease progression in the EGFR-TKI group is 1.46 times that in the chemotherapy group 
(95% CI (1.29, 1.65)). This result is consistent in the subgroups of male, smoker, and patients with 
all subtypes of non-small-cell lung cancer. However, there is no significant difference of hazard 
of disease progression among subgroups of female and non-smoker. 
Among EGFR mutant patients, the efficacy of EGFR-TKIs is superior to chemotherapy. 
Random effects model estimated the hazard of progression in the EGFR-TKI group to be 0.33  
times that in the chemotherapy group (95% CI (0.24, 0.46)). Fixed effect model estimates the 
hazard of progression in the EGFR-TKIs group to be 0.32 times that in the chemotherapy group 
(95% CI (0.27, 0.38)).This result is consistent in the subgroups of current smoker, non-smoker, 
male and female. There is no significant difference of hazard of disease progression among 
subgroup of past smoker (𝑃𝑜𝑜𝑙𝑒𝑑 𝐻𝑅 = 0.83 𝑤𝑖𝑡ℎ 𝑎 95% 𝐶𝐼 (0.36, 1.92)). 
Although EGFR-TKIs have provided an alternate solution for advanced non-small-cell 
patients, it cannot benefit all patients. Among patients not harboring EGFR mutation, it could be 
more hazardous than chemotherapy. Among Patients harboring EGFR mutation, it has shown 
significantly better efficacy than chemotherapy. However, the efficacy of EGFR-TKIs vary 
considerably among patients who had history of smoking. There is evidence that even among 
EGFR mutant patients, smoking could hinder the efficacy of EGFR-TKIs. The hazard of disease 
progression of past smokers is even greater than that of current smokers. More research needs to 
be done to further explore the pathological relationship between smoking and EGFR-TKI efficacy. 
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1. Introduction 
1.1. Overview of Lung Cancer：Public Health Significance 
Lung cancer is one of the major public health threats and leading causes of death all over 
the world. In 2012, lung cancer was the most common cancer worldwide, with 1.82 million new 
cases of lung cancer comprising 13% of all new cancer diagnoses. (1) The mortality-to-incidence 
rate ratio, which serves as an indirect measure of cancer survival, of lung cancer is 0.87. (2) The 
high incidence coupled with the high fatality of this disease has made lung cancer the most 
common cause of cancer death in the world, responsible for approximately 20% of all cancer 
deaths. (1) Due to constrained medical resources and limited treatment options, lung cancer poses 
an even more severe public health problem to developing countries, such as China. The incidence 
rate of lung cancer in China has been rising rapidly in recent years. For example, in Beijing, the 
incidence rate has increased 38.8% from 39.30 cases per 100,000 population to 54.55 cases per 
100,000 population from 1998 to 2007. (3) It is anticipated that by 2025, there will be more than 
1 million individuals diagnosed with lung cancer in China. This will make China the country with 
most lung cancer cases in the world. (4) 
Many risk factors are proven to be associated with lung cancer, such as air pollution and 
cigarette smoking. (4) Air pollution has undoubtedly intensified the public health burden of lung 
cancer in China as byproducts of China’s relentless socioeconomic development in the past 
decades. With the rapid industrialization process, the air quality continues to deteriorate in China. 
Many cities in China are often shrouded with a blanket of toxic smog with high concentration of 
fine particulate matter (PM 2.5), which is considered to be one of the most detrimental particles to 
health. According to the U.S. Embassy’s air quality monitor in Beijing, the PM 2.5 concentration 
on 12/21/2015 reached a very unhealthy level of 156 micrograms per cubic meter that could cause 
 - 2 - 
 
severe respiratory effects and lung diseases, with the World Health Organization’s maximum 
recommendation limit of 25 micrograms per cubic meter.  (5) 
Furthermore, China remains the largest consumer of cigarettes in the world with 350 
million smokers and 740 million passive smokers. (6) Each year, China process about 2.66 million 
tons of tobacco leaves, which approximately equals one-third of world’s total tobacco leaf 
production. (6) If the Chinese government does not effectively control air pollution and regulate 
cigarette sales, there is no doubt that incidence rate of lung cancer will further increase in the future.  
1.2. Treatment Strategies and Latest Progress 
There are two types of lung cancer based on the morphological differences of the lung 
tumor, namely small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). Non-
small-cell lung cancer approximately accounts for 80-85% of all lung cancers. (7) At the time of 
diagnosis with non-small-cell lung cancer, more than 30% of patients are at the late stage of the 
disease. (7) Due to the limited methods of treatment, the 5-year survival rate of non-small-cell lung 
cancer patients are often less than 15%. (7) As a consequence, the treatment strategy of non-small-
cell lung cancer has become one of the most active clinical research areas.  
Differentiated by starting lung cells, non-small-cell lung cancer is further divided into three 
main subcategories, adenocarcinoma, squamous cell (epidermoid) carcinoma and large cell 
(undifferentiated) carcinoma. Other types of non-small-cell lung cancer, including adenosquamous 
carcinoma and sarcomatoid carcinoma are very rare. (7) However, the treatment and prognosis of 
all types of non-small-cell lung cancers are often very similar. 
Depending on the stage of the lung cancer and patient characteristics, multiple treatment 
options are available for non-small-cell lung cancer patients, including surgery, chemotherapy, 
radiotherapy, immunotherapy, radiofrequency ablation and targeted therapy. Among all of the 
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options, surgery is the first choice for those patients in early stage of non-small-cell lung cancer 
because it has the highest possibility of cure. However, for those patients diagnosed at advanced 
stage who cannot benefit from surgery, the efficacy of traditional radiotherapy and chemotherapy 
are often unsatisfactory due to a lack of specificity and severe adverse effects.  
In recent years, molecular targeted therapy toward the tumor signaling transduction 
pathways has gradually become the focus of non-small-cell lung cancer treatment research. After 
a long period of plateau, scientists have made breakthroughs in the research and application of 
molecular targeted therapy.  
With the development of molecular biology, scientists have a much more clear 
understanding of tumor signaling transduction pathways, and have identified more and more lung 
cancer molecular targets, including EGFR mutation, BRAF mutation, KRAS mutation, ALK 
mutation, and ROS1 fusion. Targeted medicines based on these gene mutations has inaugurated a 
new era for non-small-cell lung cancer treatment and offered hope for patients with advanced stage 
non-small-cell lung cancer. Compared with traditional chemotherapy and radiotherapy, targeted 
therapy could greatly reduce the recurrence rate and prevent metastasis of the tumor without 
eliciting severe adverse effects for some patients.  
There are mainly three types of targeted medicine based on different transduction pathways 
in non-small-cell lung cancer treatment, namely, epidermal growth factor receptor – tyrosine 
kinase inhibitors, angiogenesis inhibitors and multi targeted antiangiogenic tyrosine kinase 
inhibitors. Among all signaling transduction pathways, epidermal growth factor receptor is the one 
with the most well-developed research and proven evidence of efficacy. Epidermal growth factor 
receptor - tyrosine kinase inhibitors, such as erlotinib, gefitinib, and afatinib have become the 
standard first line treatment for advanced stage non-small-cell lung cancer patients.  
 - 4 - 
 
Because EGFR-TKIs have a specific target, they are not believed to benefit all non-small-
cell lung cancer patients. Some research has shown that Asian, non-smoker and females have a 
relatively higher response rate of EGFR-TKIs. Other research has shown that the response rate 
among patients with EGFR mutation could reach 50% to 80%. The response rate among patients 
without EGFR mutation is only 10%-15%. (8, 9) 
1.3. Motivation Behind this Thesis 
Although there are multiple researches trying to explore the efficacy of EGFR-TKIs in 
treatment of none-small-cell lung cancer. They are, to certain degree, subject to bias and might not 
be representative. There has not been a high quality meta-analysis that systematically synthesized 
those single studies to establish a pooled estimate both in population and representative subgroups.   
Through this study, we try to provide clinicians with reliable evidence in treatment of non-small-
cell lung cancer by systematically reviewing a variety of high-quality, representative randomized 
clinical trials.  
2. Methods 
In this study, we conducted a meta-analysis synthesizing 9 randomized controlled clinical 
trials to systematically compare the effectiveness of EFGR-TKIs (Gefitinib, Erlotinib, Afatinib) 
and chemotherapy in treatment of non-small cell lung cancer among two patient populations: 
unselected patients with unknown EGFR mutation status and selected patients harboring EGFR 
mutation. The study therefore has two primary objectives: 
 1) Explore the efficacy of EGFR-TKIs compared with chemotherapy among unselected 
patients;  
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2)  Explore the efficacy of EGFR-TKIs compared with chemotherapy among EGFR mutant 
patients.  
2.1. Study Identification and Selection  
2.1.1. Criteria for Inclusion and Selection 
Randomized controlled trials that included treatment arms receiving EGFR-TKIs and 
treatment arms receiving chemotherapy were considered for inclusion in this systematic review. 
Non-randomized studies were not eligible for inclusion. Prior to enrolling in the trials patients 
must be naïve to chemotherapy but could have had resection before. All studies must have included 
patients that were followed for at least 12 months and reported progression free survival. The 
primary endpoint of interest is progression free survival because it is a clinically-relevant shorter-
term endpoint that is less likely to be affected by subsequent therapies.  
2.1.2. Literature Search Strategy 
We searched Pubmed, Cochrane Library and EMBASE with the following key words: 
EGFR, EGFR-TKIs, epidermal growth factor receptor, gefitinib, erlotinib, afatinib, NSCLC, non-
small-cell lung cancer, adenocarcinoma, large cell lung cancer, squamous cell carcinoma, 
adenosquamous carcinoma, sarcomatoid carcinoma. We firstly keep records of papers based on 
whether the title is relevant. We then browsed the abstract of each paper to decide whether it is 
qualified for further review. Non-relevant studies were then excluded. The following information 
were also recorded: title, author, year of publication, journal name, patient characteristics, 
interventions and outcome variables. We initially identified a total of 127 papers. First screening 
excluded 97 of those. Reason for exclusion includes non-relevant topics, outdated research, 
duplication and observational/retrospective study. After reading the abstract of the remaining 30 
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papers, we then excluded 15 more studies. Among excluded studies, 9 enrolled patients who were 
not naïve to chemotherapy and 6 studies did not contain our interested treatment arms or endpoints. 
We then carefully read the full text of the remaining 15 studies. Among those, 6 were excluded 
because they are not randomized controlled trials. Finally, a total of 9 randomized clinical trials 
were retained. Figure 1 shows a flow chart of the literature selection process.   
Figure 1 Study Selection Flow Diagram 
 
2.2. Assessment of Risk of Bias Criteria 
Risk of bias was assessed for each study using Effective Practice and Organization of Care 
(EPOC) criteria. Table 1 describes the nine domains that were evaluated for each study to 
determine bias. These domains evaluate potential biases including selection bias, performance bias, 
detection bias, attrition bias, and reporting bias. Each study was rated as having low risk, high risk 
or unclear risk of bias for each domain. Low risk of bias indicates that the bias is unlikely to affect 
results. High Risk of bias indicates that bias could have affected results. Unclear risk of bias 
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indicates that the assessment of bias could not be adequately made or that some doubts exist about 
the results. The risk of bias summary and risk of bias graph were generated by RevMan 5.3.   
Table 1 EPOC Risk of Bias Assessment Criteria 
Risk of Bias Domain Low Risk of Bias High Risk of Bias 
Was the allocation sequence 
adequately generated? 
A random component in the 
sequence generation process 
is described 
A nonrandom method is used 
Was the allocation adequately 
concealed? 
The unit of allocation was by 
institution, team or 
professional and allocation 
was performed on all units at 
the start of the study 
The unit of allocation was by 
patient or episode of care and 
there was some form of 
centralized randomization 
scheme, an on-site computer 
system or sealed opaque 
envelopes were used 
Were baseline outcome 
measurements similar? 
Performance or patient 
outcomes were measured 
prior to the intervention, and 
no important differences were 
present across study groups 
Important differences were 
present and not adjusted for in 
analysis 
Were baseline characteristics 
similar? 
Baseline characteristics of the 
study and control providers 
are reported and similar 
There is no report of 
characteristics in text or tables 
or if there are differences 
between control and 
intervention providers 
Were incomplete outcome 
data adequately addressed? 
Missing outcome measures 
were unlikely to bias the 
results 
Missing outcome data was 
likely to bias the results 
Was knowledge of the 
allocated interventions 
adequately prevented during 
the study? 
Authors state explicitly that 
the primary outcome variables 
were assessed blindly, or the 
outcomes are objective 
Outcomes were not assessed 
blindly 
Was the study adequately 
protected against 
contamination? 
Allocation was by 
community, institution or 
practice and it is unlikely that 
the control group received the 
intervention 
It is likely that the control 
group received the 
intervention 
Was the study free from 
selective outcome reporting? 
There is no evidence that 
outcomes were selectively 
reported 
Some important outcomes are 
subsequently omitted from the 
results 
Was the study free from other 
risks of bias? 
No evidence of other risk of 
biases 
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2.3. Data Extraction 
The following variables from each RCT were recorded: specific EGFR-TKI medicine, dose, 
chemotherapy plan, number of patients in both experimental group and controlled group, time of 
the study, region and patient characteristics including gender, age, and stage of the cancer. 
Information contained in survival curves and hazard ratios were recorded.  
2.4. Measuring the Treatment Effect 
Hazard ratio and its 95% CI of progression free survival was recorded. We converted these 
into log scale. The standard error of log hazard ratio was computed using the following formula: 
𝑆𝑒(𝑙𝑜𝑔𝐻𝑅) =
log HR−log (lower bond of 95% 𝐶𝐼)
1.96
  
2.5. Statistical Analysis 
2.5.1. Computing 
Statistical analyses were conducted using the “meta” package in the R statistical software 
program.  
2.5.2. Assessment of Heterogeneity 
Cochran’s Q test was used to evaluate the heterogeneity between each single study. The I2 
statistic and the chi-square test were used to determine if significant heterogeneity was present.  
An I2 larger than 75% and a p-value < 0.05 indicated high heterogeneity and a random effects 
model should be used. Otherwise, fixed effect model would be sufficient. In addition, we reported 
the estimates from both random effects model and fixed effect model. The pooled estimates were 
presented by forest plots. 
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2.5.3. Assessment of Publication Bias 
Linear regression test of funnel plot asymmetry (Egger’s test) was used to examine 
publication bias.  
2.5.4. Subgroup Analyses 
For the unselected patients, we performed subgroup analyses based on smoking status, 
gender and cancer type. For the EGFR mutant patients, we performed subgroup analyses based on 
smoking status and gender.  
3. Results 
3.1. Description of the Studies Included 
We included a total of 9 randomized clinical trials published between 2008 and 2014, all 
in English. (10-18). All trials have two treatment arms, EGFR-TKIs and chemotherapy. Four trials 
were conducted in Asia (2 in China, 2 in Japan). Four trials were conducted in Europe (2 in Italy, 
1 in Spain, 1 in France). One trial was conducted in the U.S. As a result, the samples are 
representative geographically. Although we wanted to understand the efficacy of EGFR-TKIs 
among African patients, we failed to find any randomized trial in Africa. We did not observe 
significant difference between median ages of patients in each study (58-71). We observed some 
imbalances between sample sizes, ranging from 103 to 973. Five studies enrolled only patients 
harboring EGFR mutation (Maemodo 2010, Zhou 2011, Wu 2014, Rosell 2012 and Miisudomi 
2010). The remaining four trials enrolled unselected patients. In terms of treatment plan, four of 
the RCTs used Erlotinib as first line EGFR-TKIs treatment, four trials used Gefitinib as first line 
EGFR-TKIs treatment and one trial used Afatinib as first line EGFR-TKIs treatment. 
Chemotherapy treatment included Cisplatin, Gemcitabine, Paclitaxel, and Vinorelbine. All 
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patients enrolled in these studies were either in stage IIIB or IV. Most of the patients had 
adenocarcinoma or squamous cell carcinoma. A small portion of them had large cell cancer and 
adenosquamous carcinoma. All of the studies reported progression free survival statistics and the 
hazard ratios. Overall, these studies included patients with a variety of demographical and clinical 
characteristics and are therefore considered to be representative. Table 2 shows the detailed 
information by treatment arm of each study included in this review.  
Table 2 Characteristics of Included Studies 
Study Group Treatment  Plan Gender 
 (M/F) 
Median 
Age 
Stage Classification 
 
 
Gridelli  
2012 
EGFR Erlotinib 150 mg/d  
252/128 
 
63 
46 IIIB 
334 IV 
170 SCC+ LCC 
210 AC + Other 
Chemo Cisplatin 80 mg/m2 
Gemcitabine 1200 
mg/m2 
 
252/128 
 
62 
37 IIIB 
343 IV 
170 SCC+ LCC 
210 AC + Other 
 
 
 
Maemodo  
2010 
EGFR Gefitinib 250 mg/d  
42/72 
 
63.9 
 
15 IIIB 
88 IV 
103 AC 
1 LCC 
2 ACC 
3 SCC 
5 Other 
Chemo Paclitaxel 200 mg/ m2 
Carboplatin AUC 6 
 
41/73 
 
62.6 
 
21ⅢB  
84 Ⅳ 
110 AC 
0 LCC 
1 ACC 
2 SCC 
1 Other 
 
 
Zhou 
2011 
EGFR Erlotinib 150 mg/d  
34/48 
 
57 
11 IIIB  
71 IV 
72 AC 
10 Other 
Chemo Gemcitabine 1000 mg/ 
m2 
Carboplatin AUC 5 
 
29/43 
 
59 
5 IIIB 
67 IV 
62 AC 
10 Other 
 
Wu 
2014 
EGFR Afatinib 40 mg/d 
 
 
 
87/155 
 
58 
16 IIIB 
226 IV 
N/A 
Chemo Gemcitabine 1000 mg/ 
m2 
Cisplatin 75 mg/ m2 
39/83 58 6 IIIB 
116 IV 
N/A 
 
 
 
Crino 2008 
EGFR Gefitinib 250mg/d  
75/22 
 
74 
 
IIIB or 
IV 
(detailed 
number 
not 
reported) 
47 SCC 
34 AC 
14 LCC 
2 Other 
Chemo Vinorelbine Tartrate 
30mg/ m2 
 
73/26 
 
74 
44 SCC 
45 AC 
7 LCC 
3 Other 
 
 
EGFR Erlotinib 150 mg/d  
23/29 
 
N/A 
7 IIB 
45 IV 
26 AC 
26 Other 
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Lilenbaum 
2008 
Chemo Carboplatin Auc 5 
Taxol 200 mg/ m2 
 
28/23 
 
N/A 
7 IIB 
44 IV 
32 AC 
19 Other 
 
 
Morère 2010 
EGFR Gefitinib 250mg/d  
38/5 
 
70 
7 IIB 
36 IV 
 
 
13 SCC 
22 AC 
8 Other 
Chemo I Gemcitabine 
1250 mg/ m2 
34/8 71 10 IIB 
32 IV 
13 SCC 
21 AC 
8 Other 
Chemo 
II 
Taxotere 
75 mg/ m2 
 
33/9 
 
71 
6 IIB 
36 IV 
9 SCC 
19 AC 
14 Other 
 
 
 
 
 
Rosell 
2012 
EGFR Erlotinib 150 mg/d  
28/58 
 
 
65 
6 IIB 
78 IV 
82 AC 
3 LCC 
1 SCC 
Chemo  1. 
Cisplatin 75 mg/ m2 + 
Docetaxel 75 mg/ m2 
or Gemcitabine 1250 
mg/ m2 
2.  
Carboplatin AUC 6 
Docetaxel 75 mg/ m2 
3. 
Carboplatin AUC 5 
Gemcitabine 1000 mg/ 
m2 
 
 
 
19/68 
 
 
 
65 
 
 
 
5 IIB 
82 IV 
 
 
 
80 AC 
1 LCC 
6 Other 
 
 
 
Mitsudomi 
2010 
 
EGFR Gefitinib 250 mg/d  
27/59 
 
64 
10 IIB 
41 IV 
224 AC 
58  LCC 
239 SCC 
65 OTER 
Chemo Docetaxel 60 mg/ m2 
Cisplatin 780 mg/ m2 
 
26/60 
 
64 
9 IIB 
41 IV 
221 AC 
52  LCC 
243 SCC 
70 OTER 
AC: adenocarcinoma; SCC: squamous cell carcinoma; LCC: large cell carcinoma; ACC: adenosquamous carcinoma; PFS: progression free survival  
 
3.2. Assessing Risk of Bias 
We carefully reviewed each entry in the Effective Practice and Organization of Care 
(EPOC) criteria to evaluate the potential sources of bias. Overall, the quality of these studies was 
found to be good. All of these studies have properly randomized patients to treatment arms and 
reported the procedure. Furthermore, there were no severe problems in allocation concealment, 
incomplete data and selective reporting. Most of the studies properly balanced the baseline 
characteristics of patients. However, most of the studies we included either did not report the 
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blinding information or were not blinded among clinicians and patients. That might be a potential 
source of bias. Figure 2 and figure 3 visualized the risk of bias information.  
 
Figure 2 Risk of Bias Graph 
 
 
Figure 3 Risk of Bias Summary 
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3.3. Primary Outcomes 
3.3.1. The Efficacy of EGFR-TKIs among Unselected Patients 
In this section, we included a total of 4 randomized clinical trials. From table 1, the studies 
described in Gridelli 2012, Crino 2008, Lilenbaum 2008, Morère 2010 were included in this 
analysis. Morère 2010 had two controlled chemotherapy treatment groups (Gemcitabine 1250 
mg/m2 and taxotere 75 mg/ m2) so we divided it into two separate studies for the purpose of analysis. 
Rosell 2012 had three chemotherapy treatment plans for the chemotherapy group. However they 
analyzed those three groups as an integrated chemotherapy group and only reported one hazard 
ratio. All studies reported progression free survival statistics and we pooled the hazard ratios of 
these studies. The forest plot shown in Figure 4 reports the detailed results.  
Figure 4 Forest Plot of Hazard Ratios among Unselected Patients 
 
The amount of heterogeneity in the true hazard ratio is estimated to be 2 = 0. The 𝐼2 =
0%, suggesting minimal heterogeneity. In addition, Cochran’s Q test of heterogeneity suggests 
that no statistically significant heterogeneity is present with p-value = 0.756. Therefore a fixed 
effect model would be sufficient. We reported the estimates from both random effects model and 
fixed effect model. Both models give same results and suggest that among unselected patients, the 
progression free survival in EGFR-TKIs group is worse than that in chemotherapy group. 
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Specifically, the hazard of progression in the EGFR-TKI group is 1.46 times that in the 
chemotherapy group (pooled HR =1.46 with a 95% CI (1.29, 1.65)). Based on linear regression 
test of funnel plot asymmetry shown in Figure 5 (Egger’s test), we fail to find evidence of 
asymmetry (t = -1.2448, df = 3, p-value = 0.3016) suggesting publication bias is not a concern. 
Figure 5 Funnel Plot of Asymmetry I 
 
Two studies (Gridelli 2012 and Lilenbaum 2008) also reported hazard ratios based on 
stratified analysis of smoking status, gender, and cancer type. We then also conducted subgroup 
analyses based on these stratifications. The result is consistent among subgroups of male, smokers, 
and patients with adenocarcinoma and other types of cancer. However, among females and non-
smokers, we did not observe significant difference of hazard of disease progression between 
EGFR-TKIs group and chemotherapy group. 
The hazard of disease progression among male patients who received EGFR-TKIs is 
significantly greater than that of male patients who received chemotherapy. Fixed effect model 
estimates the hazard of progression in the EGFR-TKI group to be 1.99 times that in the 
chemotherapy group (pooled HR = 1.99 with a 95% CI (1.48, 2.66)). Random effects model 
estimates the hazard of progression in the EGFR-TKI group to be 2.10 times that in the 
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chemotherapy group (pooled HR = 2.10 with a 95% CI (1.35, 3.26)). (Figure 6). We did not 
observe significant difference of hazard of disease progression among female patients who 
received EGFR-TKIs or chemotherapy. Both fixed effect model and random effects model 
estimates the hazard of progression in the EGFR-TKI group to be 1.15 times that in the 
chemotherapy group (pooled HR = 1.15 with a 95% CI (0.91, 1.46)). (Figure 7).  
Figure 6 Forest Plot of Hazard Ratios among Unselected Male Patients 
 
Figure 7 Forest Plot of Hazard Ratios among Unselected Female Patients 
 
The hazard of disease progression among smokers who received EGFR-TKIs is 
significantly greater than that of smokers who received chemotherapy. Fixed effect model 
estimates the hazard of progression in the EGFR-TKI group to be 1.87 times that in the 
chemotherapy group (pooled HR = 1.87 with a 95% CI (1.59, 2.20)). Random effects model 
estimates the hazard of progression in the EGFR-TKI group to be 2.10 times that in the 
chemotherapy group (pooled HR = 2.05 with a 95% CI (1.37, 3.08)). (Figure 8). 
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Figure 8 Forest Plot of Hazard Ratios among Unselected Smoker 
 
We did not observe significant difference of hazard of disease progression among non-
smoking patients who received EGFR-TKIs or chemotherapy. Both random effects and fixed 
effect model estimates the hazard of progression in the EGFR-TKI group to be 0.89 times that in 
the chemotherapy group (pooled HR = 0.89 with a 95% CI (0.64, 1.22)). (Figure 9).  
Figure 9 Forest Plot of Hazard Ratios among Unselected Non-smoker 
 
The hazard of disease progression among adenocarcinoma patients who received EGFR-
TKIs is significantly greater than that of adenocarcinoma patients who received chemotherapy. 
Both fixed effect model and random effects model estimates the hazard of progression in the 
EGFR-TKI group to be 1.46 times that in the chemotherapy group (pooled HR = 1.46 with a 95% 
CI (1.20, 1.76)). (Figure 10).  
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Figure 10 Forest Plot of Hazard Ratios among Unselected Patients with adenocarcinoma 
 
Among patients with other types of NSCLC, the fixed effect model suggest a greater hazard 
of disease progression of patients in the EGFR-TKIs group. However, random effects model 
suggests that there is no significant difference of hazard of disease progression of patients in 
EGFR-TKIs group and chemotherapy group. In this case, the amount of heterogeneity in the true 
hazard ratio is estimated to be 2 = 1407. The 𝐼2 = 44.7%, suggesting minimal heterogeneity. In 
addition, Cochran’s Q test of heterogeneity suggests that no statistically significant heterogeneity 
is present with p-value = 0.1788. As a result, fixed effect model would be sufficient. Fixed effect 
model estimates the hazard of progression in the EGFR-TKI group to be 1.61 times that in the 
chemotherapy group (pooled HR = 1.61 with a 95% CI (1.29, 2.02)). Random effects model 
estimates the hazard of progression in the EGFR-TKI group to be 1.90 times that in the 
chemotherapy group (pooled HR = 1.90 with a 95% CI (0.97, 3.70)). (Figure 11).  
Figure 11 Forest Plot of Hazard Ratios among Unselected Patients with Other Types of NSCLC 
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3.3.2. The Efficacy of EGFR-TKIs among Patients Harboring EGFR Mutation 
Six trials reported the progression free survival statistics among patients harboring EGFR 
mutation (Gridelli 2012, Maemodo 2010, Zhou 2011, Wu 2014, Rosell 2012, Mitsudomi 2010). 
We pooled the hazard ratios. The forest plot below (Figure 12) shows the detailed results. The 
amount of heterogeneity in the true hazard ratio is estimated to be 2 = 0.1043. The 𝐼2 = 71.8%, 
suggesting maximal heterogeneity. In addition, Cochran’s Q test of heterogeneity suggests that 
statistically significant heterogeneity is present with p-value = 0.0033. Therefore a random effects 
model should be used. We reported the estimates from both random effects model and fixed effect 
model. Both models give similar results and suggest that among EGFR mutant patients, the 
progression free survival in EGFR-TKIs group is superior to that in chemotherapy group. Random 
effects model estimates the hazard of progression in the EGFR-TKI group to be 0.33 times that in 
the chemotherapy group (pooled HR = 0.33 with a 95% CI (0.24, 0.46)). Fixed effect model 
estimates the hazard of progression in the EGFR-TKI group to be 0.32 times that in the 
chemotherapy group (pooled HR = 0.32 with a 95% CI (0.27, 0.38)). (Figure 12) Based on linear 
regression test of funnel plot asymmetry (Egger’s test), we fail to find evidence of asymmetry          
(t = 0.3712, df = 4, p-value = 0.7293), suggesting publication bias is not a concern. (Figure 13).  
Figure 12 Forest Plot of Hazard Ratios among Selected EGFR Mutant Patients 
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Figure 13 Funnel Plot of Asymmetry II 
 
Four studies also performed stratified analyses based on smoking status and gender 
(Mitsudomi 2010, Rosell 2012, Wu 2014 and Zhou 2011). In terms of smoking status, Rosell 2012 
and Wu 2014 divided patients into three subgroups: current smoker, non-smoker and past smoker. 
Mitsudomi 2010 and Zhou 2011 combined the past smoker and current smoker as one subgroup. 
As a consequence, we pooled the hazard ratios of current smokers from all four studies. But we 
only used Rosell 2012 and Wu 2014 for past smoker and current smoker analyses. The results are 
consistent across male, female and patients who never smoked. Among current smokers, although 
the hazard of disease progression is lower in EGFR-TKIs group, it is less significant than that in 
non-smokers. An interesting fact is that, among past smokers, the hazard ratio of disease 
progression between EGFR-TKIs group and chemotherapy is not significantly different from 1. 
With a very large variance of hazard ratio, the efficacy of EGFR-TKIs among patients who smoked 
in the past varies significantly. Many patients who had a history of smoking but quit later did not 
benefit from EGFR-TKIs even though they were EGFR mutant. Both fixed effect model and 
random effects model give same estimates of HR = 0.83 with 95% CI (0.36, 1.92). We were 
surprised that among EGFR mutant patients, the hazard of disease progression of past smokers is 
even greater than that of current smokers (HR=0.48, 95% CI = (0.25, 0.92). However, we only 
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included two studies so that this result may subject to bias. More research in this area needs to be 
done to further address this question.   
We did not observe significant difference of hazard of disease progression among past 
smokers who received EGFR-TKIs or chemotherapy. Both fixed effect model and random effects 
model estimates the hazard of progression in the EGFR-TKI group to be 0.83 times that in the 
chemotherapy group (pooled HR = 0.83 with a 95% CI (0.36, 1.92)). (Figure 14).  
Figure 14 Forest Plot of Hazard Ratios among Selected EGFR Mutant Patients Who are Past Smoker 
 
The hazard of disease progression among current smokers who received EGFR-TKIs is 
significantly lower than that of current smokers who received chemotherapy. Both fixed effect 
model and random effects model estimates the hazard of progression in the EGFR-TKI group to 
be 0.48 times that in the chemotherapy group (pooled HR = 0.48 with a 95% CI (0.25, 0.92)). 
(Figure 15). 
Figure 15 Forest Plot of Hazard Ratios among Selected EGFR Mutant Patients Who are Current Smoker 
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The hazard of disease progression among non-smokers who received EGFR-TKIs is 
significantly lower than that of non-smokers who received chemotherapy. Random effects model 
estimates the hazard of progression in the EGFR-TKI group to be 0.25 times that in the 
chemotherapy group (pooled HR = 0.25 with a 95% CI (0.16, 0.40)). Fixed effect model estimates 
the hazard of progression in the EGFR-TKI group to be 0.26 times that in the chemotherapy group 
(pooled HR = 0.26 with a 95% CI (0.21, 0.3)). (Figure 16). 
Figure 16 Forest Plot of Hazard Ratios among Selected EGFR Mutant Patients Who are Non-smoker 
 
The hazard of disease progression among male who received EGFR-TKIs is significantly 
lower than that of male who received chemotherapy. Random effects model estimates the hazard 
of progression in the EGFR-TKI group to be 0.38 times that in the chemotherapy group (pooled 
HR = 0.38 with a 95% CI (0.26, 0.56)). Fixed effect model estimates the hazard of progression in 
the EGFR-TKI group to be 0.38 times that in the chemotherapy group (pooled HR = 0.38 with a 
95% CI (0.28, 0.53)). (Figure 17). 
The hazard of disease progression among female who received EGFR-TKIs is significantly 
lower than that of female who received chemotherapy. Random effects model estimates the hazard 
of progression in the EGFR-TKI group to be 0.28 times that in the chemotherapy group (pooled 
HR = 0.28 with a 95% CI (0.217, 0.47)). Fixed effect model estimates the hazard of progression 
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in the EGFR-TKI group to be 0.30 times that in the chemotherapy group (pooled HR = 0.30 with 
a 95% CI (0.23, 0.39)). (Figure 18). 
Figure 17  Forest Plot of Hazard Ratios among Selected EGFR Mutant Male Patients  
 
Figure 18 Forest Plot of Hazard Ratios among Selected EGFR Mutant Female Patients 
 
4. Conclusion and Discussion 
In this meta-analysis, we systematically evaluated the efficacy of EGFR-TKIs compared 
with chemotherapy. We included 9 relatively high quality randomized controlled trials which 
enrolled patients with different clinical characteristics.  Statistical analysis shows that among 
unselected patients (unknown EGFR mutation status), the efficacy of EGFR-TKIs is inferior to 
chemotherapy. In the EGFR-TKI group, the hazard of disease progression is significantly higher 
than that in chemotherapy group. However, among females and non-smokers with unknown EGFR 
mutation status, we did not observe significant difference of hazard of disease progression between 
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the EGFR-TKI group and the chemotherapy group. Among patients harboring EGFR mutation, 
EGFR-TKIs showed superb efficacy. The hazard of disease progression in the EGFR-TKIs group 
is significantly lower than that in chemotherapy group. However, patient’s smoking status can 
greatly affect the efficacy. Among current smokers, although the hazard of disease progression is 
lower in EGFR-TKIs group, it is less significant than that in non-smokers. Among past smokers, 
the hazard ratio of disease progression between the EGFR-TKIs group and the chemotherapy 
group is not significantly different from 1. The efficacy of EGFR-TKIs among patients who 
smoked in the past varies significantly. Many patients who had a history of smoking but quit later 
did not benefit from EGFR-TKIs even though they were EGFR mutant.  
Although EGFR-TKIs have provided an alternate solution for advanced non-small-cell 
patients, it cannot benefit all patients. For some patients, it might be less effective and more 
hazardous than the traditional chemotherapy. EGFR mutated patients are most sensitive to EGFR-
TKIs and have the best prognosis. A few studies have paid attention to patient’s smoking status. 
However, most of those studies classified patients to either smoker or non-smoker. In this meta-
analysis, we found evidence that the efficacy of EGFR-TKIs among past smokers could be worse 
than that among current smoker. However, there is no formal definition of past smoker. In Wu 
2014, they define past smoker as those who smoked less than 15 pack per year and stopped more 
than 1 year ago before enrolling to the trial. Rosell 2012 did not clarify the definition of past 
smoker. However, this unexpected finding shed some light to future research on this topic. More 
research needs to be done to further explore the pathological relationship between smoking status 
and efficacy of EGFR-TKIs. Formal standard needs to be established to distinguish between 
former smoker and current smoker. For example, how many cigarettes per day does a person 
smoke makes him a smoker? Who should be clarified as former smoker? For how long has a person 
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need to quit smoking to be considered for former smoker? Moreover, what category should passive 
smoker fall in? How does the efficacy of EGFR-TKIs among passive smokers compared to 
chemotherapy?  
5. The Future of Cancer Treatment  
The current cancer treatment is largely based on evidence-based medicine. Clinicians make 
medical decisions based on macro-level characteristics such as gender, age, smoking status and 
cancer type.  However, even some of those are significantly associated with prognosis, they cannot 
perfectly predict prognosis because they cannot differentiate the fundamental characteristics of 
each patient. Two patients can have exactly same clinical characteristics but does that guarantee 
their prognosis will also be same? What really differentiate each person is their unique genetic 
makeup. If scientists could uncover the molecular biomarkers that drive individual variability 
in clinical responses, then clinicians can then build genetic “regression model” to ensure the best 
prognosis possible and even prevent cancer from happening. In the future, we look forward to 
seeing the medical science come down from macro level to micro level and every patient can 
receive a “personalized medicine” that is specifically designed to him/her.     
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Appendix R-Code 
Library(meta) 
### The efficacy of EGFR-TKIs among unselected patients 
> unselected = data.frame( 
+ yi=c(0.4252677354,0.1739533071,0.3715635564,0.3011050928,0.4004775666), 
+ vi=c(0.0792043868,0.1716695085,0.1998807468,0.230065419,0.2296272522)) 
> res=metagen(yi,vi,sm="HR",data=unselected) 
> forest(res) 
> funnel(res) 
> metabias(res,method="linreg",k.min=5,plotit=TRUE) 
### Unselected Male 
> unselectedmale = data.frame( 
+ yi=c(0.5822156199,1.057790294), 
+ vi=c(0.1684611474,0.3193917743)) 
> res=metagen(yi,vi,sm="HR",data=unselectedmale) 
> forest(res) 
### Unselected Female 
> unselectedfemale = data.frame( 
+ yi=c(0.1570037488,0.0676586485), 
+ vi=c(0.1338593186,0.2867117195)) 
> res=metagen(yi,vi,sm="HR",data=unselectedfemale) 
> forest(res) 
### Unselected Smoker 
> unselectedsmoker=data.frame( 
+ yi=c(0.5988365011,1.078409581), 
+ vi=c(0.0852316758,0.3501874967) ) 
> res=metagen(yi,vi,sm="HR",data=unselectedsmoker) 
> forest(res) 
### Unselected Non-Smoker 
> unselectednonsmoker=data.frame( 
+ yi=c(-0.1165338163,-0.1625189295), 
+ vi=c(0.1682414726,0.7382239709) ) 
> res=metagen(yi,vi,sm="HR",data=unselectednonsmoker) 
> forest(res) 
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### Unselected adenocarcinoma 
> unselectedadenocarcinoma =data.frame( 
+ yi=c(0.4054651081,0.1906203596), 
+ vi=c(0.1054154333,0.2648594013)) 
> res=metagen(yi,vi,sm="HR",data=unselectedadenocarcinoma) 
> forest(res) 
### Unselected other 
> unselectedother=data.frame( 
+ yi=c(0.4446858213,1.238374231), 
+ vi=c(0.1171298172,0.5785786815)) 
> res=metagen(yi,vi,sm="HR",data=unselectedother) 
> forest(res) 
### The efficacy of EGFR-TKIs among patients harboring EGFR mutation 
> EGFR = data.frame( 
+ yi=c(-0.5108256238,-1.203972804,-1.832581464,-1.272965676,-0.9942522733,-0.7153927895), 
+ vi=c(0.3536465207,0.1582423104, 0.23979777, 0.1716695085,0.2000214734,0.19145476)) 
> res=metagen(yi,vi,sm="HR",data=EGFR) 
> forest(res) 
> funnel(res) 
> metabias(res,method="linreg",k.min=5,plotit=TRUE) 
### EGFR+ Past Smoker 
> EGFRpastsmoker=data.frame( 
+ yi=c(0.0487901642,-0.9416085399), 
+ vi=c(0.4923882123,0.8763528046)) 
> res=metagen(yi,vi,sm="HR",data=EGFRpastsmoker) 
> forest(res) 
### EGFR+ Current Smoker 
> EGFRcurrentsmoker=data.frame( 
+ yi=c(-0.5798184953,-0.7765287895), 
+ vi=c(0.6720925968,0.3763259914)) 
>  res=metagen(yi,vi,sm="HR",data=EGFRcurrentsmoker) 
> forest(res) 
### EGFR+ Non Smoker 
> EGFRnonsmoker=data.frame( 
+ yi=c(-0.7635696449,-1.427116356,-1.427116356,-1.966112856), 
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+ vi=c(0.2298232119,0.2397977,0.2068699531,0.2855182592)) 
> res=metagen(yi,vi,sm="HR",data=EGFRnonsmoker) 
> forest(res) 
### EGFR+ Male 
> EGFRmale=data.frame( 
+ yi=c(-0.398986142,-0.9675840263,-1.021651248,-1.347073648), 
+ vi=c(0.3513705136,0.4103942937,0.2749982147,0.3158363308)) 
> res=metagen(yi,vi,sm="HR",data=EGFRmale) 
>forest(res) 
### EGFR+ Female 
> EGFRfemale=data.frame( 
+ yi=c(-0.7339691751,-1.049822124,-1.427116356,-2.040220829), 
+ vi=c(0.2286901909,0.2368906164,0.268699531,0.3158363308)) 
> res=metagen(yi,vi,sm="HR",data=EGFRfemale) 
> forest(res) 
> 
 
